Investor Presentaiton
Investor presentation
Full year 2018
Slide 14
Key development milestones
Diabetes
Completion of the phase 3a PIONEER programme for oral semaglutide, following successful completion of
PIONEER 6 and 9
Oral semaglutide ready for regulatory filing. Filing expected in the USA around end-Q1 2019 with use of
priority review voucher
•
Phase 2 trial initiated for LAI287, a once-weekly insulin, to assess safety and efficacy
Obesity
Biopharm
Other serious
chronic
diseases
•
Phase 1 trial initiated for LAIsema, a fixed ratio combination of LAI287 and semaglutide
Embark Biotech and Novo Nordisk entered into a research collaboration on the discovery of novel treatments
for obesity and metabolic diseases
Successful completion of the phase 2 trial explorer4 with concizumab, which together with explorer5 data
confirmed clinical proof of concept of concizumab and phase 3 preparation is initiated
Completion of the phase 2 trial REAL 3 (extension period) for long-acting growth hormone somapacitan in GHD
Development of sc N8-GP has been discontinued
Staten Biotechnology and Novo Nordisk to collaborate on developing novel treatment for dyslipidaemia
NASH: Non-alcoholic steatohepatitis; GHD: Growth hormone deficiency; sc: subcutaneous
changing
diabetes
novo nordiskView entire presentation